Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy
New England Journal of Medicine · 14.05.2026 · 394 (19) · 1962-1963
DOI: 10.1056/nejmc2603286 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 14.05.2026. Verfasst von Richard Lafayette und 2 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University, Stanford, CA. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
To the Editor: The recent reports of clinical benefit from the inhibition of the cytokine A proliferation-inducing ligand (APRIL) or dual inhibition of B-cell activating factor (BAFF) and APRIL in IgA nephropathy (Feb. 12 issue) 1-3 are encouraging. However, the apparent contrast with the results of a previous trial 4 of anti-CD20 therapy that did not show benefit warrants mechanistic clarification. Rituximab depletes circulating CD20+ B cells but spares long-lived plasma cells and does not directly target mucosal IgA–producing niches. In IgA nephropathy, pathogenic galactose-deficient IgA1 and anti–galactose-deficient IgA1 autoantibodies may arise from mucosa-associated lymphoid tissue, in which survival signals mediated by . . .
Autor:innen und Institutionen
- Stanford University, Stanford, CA.
- Vera Therapeutics, Brisbane, CA.
- University of Leicester, Leicester, United Kingdom.
Zitieren
APA
Lafayette, R., Brenner, R. M., & Barratt, J. (2026). Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy. New England Journal of Medicine, 394(19), 1962-1963. https://doi.org/10.1056/nejmc2603286
Vancouver
Lafayette R, Brenner RM, Barratt J. Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy. New England Journal of Medicine. 2026;394(19):1962-1963. doi:10.1056/nejmc2603286
BibTeX
@article{Lafayette2026,
author = {Lafayette, Richard and Brenner, Robert M and Barratt, Jonathan},
title = {Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {19},
pages = {1962--1963},
doi = {10.1056/nejmc2603286}
}
EUVIMED